GTx
20
0
0
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
45.0%
9 terminated/withdrawn out of 20 trials
55.0%
-31.5% vs industry average
25%
5 trials in Phase 3/4
118%
13 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (20)
Phase II, Dose Finding Study of GTx-758
Role: lead
Phase II Study of GTx024 in Women With Metastatic Breast Cancer
Role: lead
Study to Assess Long-Term Safety/Tolerability of Enobosarm (GTx 024) in Stress Urinary Incontinence
Role: lead
Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass
Role: lead
GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer
Role: lead
Durability Extension Study to Assess Clinical Activity and Safety of Enobosarm (GTx-024) in Stress Urinary Incontinence
Role: lead
Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer
Role: lead
Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)
Role: lead
Study to Assess Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence
Role: lead
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Role: lead
GTx-024 as a Treatment for Stress Urinary Incontinence in Women
Role: lead
Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer
Role: lead
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Role: lead
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Role: lead
Enobosarm and Anastrozole in Pre-menopausal Women With High Mammographic Breast Density
Role: collaborator
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Role: lead
Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.
Role: lead
Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer
Role: lead
A Chemoprevention Study of an Investigational Drug in Men With High Grade Prostate Intraepithelial Neoplasia (PIN)
Role: lead
Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy
Role: lead
All 20 trials loaded